Abstract
Johnson & Johnson is teaming up with Cidara Therapeutics on a therapy that treats and prevents influenza infections. Cidara is developing antiviral conjugates, in which a virus-targeting peptide or small molecule is linked to a human antibody fragment that engages the immune system and increases the therapy’s longevity. Cidara will get $27 million from J&J to advance Cidara’s influenza compound CD388 and could earn up to $753 million more in R&D funding and milestone payments. Cidara is also developing antiviral conjugates for respiratory syncytial virus, HIV, and SARS-CoV-2.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
